EUVIMEDEUVIMED entdecken
Scoping Review

European Medicines Agency (EMA) Approval, Conditional Authorization, and Post-Authorization Evidence Gaps: Scoping Review with ☸️SAIMSARA

SAIMSARA Journal · 23.05.2026 · 1 (3)

DOI: 10.62487/saimsara9a30a35e ↗

Kurz gefasst

Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 23.05.2026. Die Arbeit nennt 95 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To map and synthesize original research on EMA certification and closely related regulatory processes, with emphasis on evidentiary standards, accelerated or conditional authorization, endpoint validation, RWE, post-authorization safety and efficacy monitoring, and implications for clinical and policy decision-making. The review uses 95 references and builds its evidence map from 96 original studies with 1421115 total participants/sample observations (topic-deduplicated ΣN). EMA certification and authorization function as lifecycle access decisions rather than endpoints of evidence generation, with timely market entry frequently coupled to residual uncertainty that must be resolved through post-authorization commitments, pharmacovigilance, and real-world evidence. This pattern is most visible in oncology and expedited pathways, where 90% of products in one expedited cohort relied on surrogate endpoints with none validated and conditional approvals were linked to less favorable added-benefit and reimbursement outcomes. Real-world evidence appeared in 39.9% of marketing authorization applications but supported efficacy decisions in only 22%, indicating that its regulatory weight remains constrained by quality and design. For clinicians and payers, this supports treating EMA approval as a starting point for ongoing benefit–risk reassessment rather than confirmation of mature value. Future work should prioritize prospective frameworks that link conditional certification to enforceable, time-bound, and methodologically rigorous confirmatory evidence.

Zitieren

APA

(2026). European Medicines Agency (EMA) Approval, Conditional Authorization, and Post-Authorization Evidence Gaps: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(3). https://doi.org/10.62487/saimsara9a30a35e

Vancouver

European Medicines Agency (EMA) Approval, Conditional Authorization, and Post-Authorization Evidence Gaps: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(3). doi:10.62487/saimsara9a30a35e

BibTeX
@article{euvimed2026,
  title = {European Medicines Agency (EMA) Approval, Conditional Authorization, and Post-Authorization Evidence Gaps: Scoping Review with ☸️SAIMSARA},
  journal = {SAIMSARA Journal},
  year = {2026},
  volume = {1},
  number = {3},
  doi = {10.62487/saimsara9a30a35e}
}
Kostenlos starten →